On June 20, Akorn, Inc. (NASDAQ:AKRX) announced that it has sold its subsidiary, ECR Pharmaceuticals (ECR), to Valeant Pharmaceuticals (NYSE/TSX: VRX) for $41 million in cash and assumption of certain liabilities. ECR, which promotes certain branded pharmaceuticals through its sales force, was acquired through the acquisition of Hi-Tech Pharmacal. In light of this divestiture, Akorn will update its annual 2014 guidance during its fiscal second quarter earnings call in early August. Akorn, Inc. (NASDAQ:AKRX) net profit margin is 15.30% and weekly performance is 8.33%. On last trading day company shares ended up $30.96. Analysts mean target price for the company is $ 30.00. Akorn, Inc. (NASDAQ:AKRX) distance from 50-day simple moving average (SMA50) is 17.02%.
Zillow, Inc. (NASDAQ:Z), the leading real estate and home-related marketplace, and Douglas Elliman Real Estate, one of the largest real estate brokerages in the nation and New York City’s largest residential brokerage, announced they have entered into a new strategic marketing partnership. Zillow Inc (NASDAQ:Z) shares fell -1.25% in last trading session and ended the day on $132.30. Z Gross Margin is 90.70% and its return on assets is -2.80%. Zillow Inc (NASDAQ:Z) quarterly performance is 40.40%.
On June 12, Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) and Progenics Pharmaceuticals reported that the Anesthetic and Analgesic Drug Products Advisory Committee of the Food and Drug Administration (FDA) has provided an assessment of potential cardiovascular risk associated with products in the class of peripherally-active opioid receptor antagonists (PAMORAS) and recommendations regarding the necessity, timing, design and size of cardiovascular outcomes trials to support approval of products in this class for the proposed indication of opioid-induced constipation (OIC) in patients taking opioids for chronic pain. Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) shares moved up 0.58% in last trading session and was closed at $125.07, while trading in range of $122.86 – $126.60. Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) year to date (YTD) performance is 39.06%.
BGC Partners (NASDAQ:BGCP)‘s stock had its “outperform” rating reaffirmed by equities researchers at Raymond James in a research report issued on Tuesday. They currently have a $8.00 price target on the stock, up from their previous price target of $7.50. Raymond James’ price objective would indicate a potential upside of 5.12% from the stock’s previous close. BGC Partners, Inc. (NASDAQ:BGCP) ended the last trading day at $7.51. Company weekly volatility is calculated as 2.02% and price to cash ratio as 2.57. BGC Partners, Inc. (NASDAQ:BGCP) showed a positive weekly performance of 1.21%.
HC Wainwright began coverage on shares of Edap – Tms SA (NASDAQ:EDAP). The firm issued a buy rating and a $6.00 price target on the stock. EDAP TMS S.A. (ADR) (NASDAQ:EDAP) shares moved down -4.07% in last trading session and was closed at $4.24, while trading in range of $4.22 – $4.52. EDAP TMS S.A. (ADR) (NASDAQ:EDAP)year to date (YTD) performance is 43.73%.